参附注射液对慢性阻塞性肺疾病急性加重期患者临床疗效和作用机制研究  

Clinical Effect Study of Shenfu Injection (SF) and Mechanism of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

作　　者：张茜利 马玉海[1] 叶和军[1] 

机构地区：[1]武警浙江省总队嘉兴医院急诊科,浙江嘉兴314000

出　　处：《辽宁中医杂志》2014年第7期1446-1448,共3页Liaoning Journal of Traditional Chinese Medicine

摘　　要：目的:探讨参附注射液(SF)对慢性阻塞性肺疾病急性加重期(AECOPD)患者临床治疗效果,并分析其作用机制,为中医辅助治疗AECOPD提供临床依据。方法:选取该院2012年1月—2013年12月AECOPD患者60例,根据治疗方法分为观察组和对照组,对照组28例,常规西医治疗。观察组32例,对照组基础上应用SF治疗。主要观察指标为治疗效果及1 s用力呼气量(FEV1)、最大肺活量(FVC)和FEV1/FVC等指标。结果:观察组总有效率为91.62%(29/32),高于对照组75.00%(21/28)(P<0.05);观察组无效率为9.38%(3/32),低于对照组25.00%(7/28)(P<0.05);治疗后两组FEV1/FVC(%)、FVC(%)和FEV1(%)均高于治疗前(P<0.05)。观察组治疗后FEV1/FVC(%)、FVC(%)和FEV1(%)分别为59.86±0.23、64.88±0.35和62.84±0.36,均高于对照组治疗后57.01±0.16、61.93±0.32和58.19±0.41(P<0.05)。结论:SF可作为COPD急性发作患者辅助治疗,能明显提高治疗效果,改善患者肺功能状况,值得临床推广使用。Objective ： To explore the effect of Shenfu Injection （SF） on acute exacerbation of chronic obstructive pulmonary disease （AECOPD） , and analyze its mechanism. To provide the clinical basis for AECOPD of the adjuvant treatment with Chinese medicine. Methods ：60 patients with AECOPD were selected in the hospital from January in 2012 to December in 2013. According to treatment methods, they were divided into observation group and control group. 28 cases in the control group used the routine treatment of Western medicine. 32 cases of the observation group were treated with SF on the basis of the control group. Main in- dex was the treatment effect and forced expiratory volume in one second （FEV1） ,forced vital capacity （FVC） and FEV1/FVC. Results：The total effective rate of the observation group was 91.62% （29/32）, higher than that of the control group 75% （21/ 28 ） （ P 〈 0.05 ）. The invalid rate of the observation group was 9.38 % （ 3/32 ）, lower than that of the control group 25 % （ 7/28 ） （ P 〈 0.05 ）. After treatment （ FEV1/FVC% ）, FVC （ % ） and FEV1 （ % ） in the two groups were higher than those before treatment （P 〈 0.05 ）. In the observation group after treatment, （ FEV1/FVC% ） , FVC （ % ） and FEV1 （ % ） were 59.86±0. 23, 64.88 ± 0.35 and 62.84 ± 0. 36 , higher than the those of control group after treatment 57.01± 0.16,61.93±0.32 and 58. 19 ~ 0.41 （P 〈 0.05 ）. Conclusion：SF could be used as adjuvant therapy in patients with acute exacerbation of COPD, and sig- nificantly improve the therapeutic effect and improve lung function status of patients, which was worthy of clinical use.

关 键 词：参附注射液(SF) 慢性阻塞性肺疾病急性加重期(AECOPD) 疗效 

分 类 号：R563[医药卫生—呼吸系统]